Thyrocare Technologies Reports Strong Growth in Q4 and FY25, Achieves 100% NABL Accreditation
Thyrocare Technologies Limited announced robust financial results for Q4 and FY25. Q4 saw a 21% YoY revenue increase to INR 187.20 crore, with 78% EBITDA growth and 88% PAT surge. FY25 annual revenue rose 20% to INR 687.30 crore, with 37% EBITDA growth and 45% PAT increase. The company became India's first 100% NABL accredited national diagnostic lab chain, processed 167.9 million tests, and expanded its franchisee network. Strategic acquisitions of Polo Labs and Vimta Labs' diagnostic business were completed. The Board recommended a final dividend of INR 21.00 per share.

*this image is generated using AI for illustrative purposes only.
Thyrocare Technologies Limited , a leading diagnostic services provider, has announced its financial results for the fourth quarter and fiscal year ended March 31, 2025, showcasing robust growth and operational achievements.
Q4 FY25 Highlights
- Consolidated revenue increased by 21% year-over-year to INR 187.20 crore
- Normalized EBITDA grew by 78% to INR 65.30 crore
- Profit after tax (excluding exceptional items) surged by 88% to INR 32.50 crore
FY25 Performance
- Annual consolidated revenue rose by 20% to INR 687.30 crore
- Normalized EBITDA for the year increased by 37% to INR 209.90 crore
- Profit after tax (excluding exceptional items) grew by 45% to INR 101.20 crore
Operational Achievements
Thyrocare reached a significant milestone by becoming India's first and only 100% NABL accredited national diagnostic laboratory chain. This accreditation covers 29 Thyrocare-owned labs across India, excluding recently acquired facilities and partner labs.
The company processed a total testing volume of 167.9 million in FY25, which it claims is the largest in terms of volume. The number of active franchisees grew by 16% to over 11,000, while the patient count increased by 11% to 16.7 million.
Strategic Expansions
During FY25, Thyrocare completed two strategic acquisitions:
- Polo Labs Private Limited: This acquisition strengthened Thyrocare's presence in Punjab, Haryana, and Himachal Pradesh.
- Clinical diagnostic business of Vimta Labs: This move expanded Thyrocare's footprint in southern India.
Additionally, the company extended its ECG at Home services to 1,150 pincodes by Q4FY25, up from 650 pincodes in Q1FY25.
Financial Position
Thyrocare's consolidated cash reserves stood at INR 191.80 crore as of March 2025. The Board of Directors has recommended a final dividend of INR 21.00 per equity share for FY25, subject to shareholder approval.
Management Commentary
Rahul Guha, Managing Director of Thyrocare Technologies Limited, stated, "Our strong performance in Q4 and throughout FY25 reflects our commitment to quality and operational excellence. The achievement of 100% NABL accreditation for our labs underscores our dedication to maintaining the highest standards in diagnostic services."
Future Outlook
With its expanded network, strategic acquisitions, and focus on quality, Thyrocare is well-positioned to capitalize on the growing demand for diagnostic services in India. The company continues to invest in technology and infrastructure to enhance its service offerings and maintain its competitive edge in the market.
Note: All financial figures are in Indian Rupees (INR).
Historical Stock Returns for Thyrocare Technologies
1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
---|---|---|---|---|---|
+0.28% | +9.01% | +14.19% | +41.00% | +81.81% | +104.46% |